Astaxanthin Supplementation in Cyclists
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Background of the study:
Astaxanthin has been shown to be a powerfull anti-oxidant. Health benefits have been shown in animals and humans. Exercise enhancing effects have been shown in animals via enhancement of fat oxidation. We want to examine the effects of 4 weeks of astaxanthin supplementation on fat oxidation and cycling performance in trained cyclists
Objective of the study:
To test the hypothesis that 4 weeks supplementation with astaxanthin will improve fat oxidation and improve exercise performance in trained cyclists
Study design:
Double blind, placebo controlled study.
Study population:
Well trained cyclists between 18-30 years old
Intervention (if applicable):
astaxanthin (20 mg/day) or placebo for 4 weeks
Primary study parameters/outcome of the study:
performance on a time trial after 90 min steady state exercise.
Secundary study parameters/outcome of the study (if applicable):
substrate use plasma glucose plasma lactate plasma free fatty acid plasma astaxanthin
Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable):
The risks involved in participating in this experiment are minimal. Astaxanthin has been shown to be safe. Insertion of the catheters in a vein is comparable to a normal blood draw and the only risk is of a small local haematoma.
| Condition | Intervention |
|---|---|
|
Athletic Performance |
Dietary Supplement: astaxanthin Dietary Supplement: placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science |
- time trial performance [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]time trial performance
- substrate use [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 24 |
| Study Start Date: | November 2010 |
| Estimated Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: astaxanthin |
Dietary Supplement: astaxanthin
astaxanthin
|
| Placebo Comparator: placebo |
Dietary Supplement: placebo
placebo
|
Eligibility| Ages Eligible for Study: | 18 Years to 30 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy
- Male
- Age between 18 and 30 years
- Endurance trained (≥3 sessions of endurance exercise per week)
- VO2 max ≥ 50 ml/kg/min
- Training history of more than one year of ≥3 sessions of endurance exercise per week
- BMI <25 kg/m2
Exclusion Criteria:
- Use of medication
- Smoking
Contacts and Locations| Contact: Peter Res, MSc | +3143381383 | peter.res@maastrichtuniversity.nl |
| Netherlands | |
| Maastricht University | Recruiting |
| Maastricht, LI, Netherlands, 6229 | |
| Contact: Peter Res, MSc +3143381383 peter.res@maastrichtuniversity.nl | |
More Information
No publications provided
| Responsible Party: | Peter Res, MUMC |
| ClinicalTrials.gov Identifier: | NCT01241877 History of Changes |
| Other Study ID Numbers: | MEC 10-3-068 |
| Study First Received: | November 15, 2010 |
| Last Updated: | April 19, 2011 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
ClinicalTrials.gov processed this record on June 17, 2013